Overview
International Biotechnology Trust tries to achieve long-term capital growth by investing primarily in biotechnology and other life sciences companies that are either quoted or unquoted and possess the potential for high growth. International Biotechnology Trust invests in companies whose shares are considered to have good prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.
You can access the manager’s website here
Fundamentals
Price
Research History
-
17 Oct 2023 14 min read
QuotedData’s Investment Companies Quarterly Review – Third Quarter 2023
Third quarter of 2023 Investment Companies | Quarterly roundup | October 2023 Kindly sponsored by abrdn ‘Uncomfortable’ Following a fast start to the first half of the year, globally equities took a breather in Q3, as markets assessed the implications of the worst bond sell-off in a generation. Yields on 10-year US treasuries and UK […]
-
07 Dec 2022 64 min read
QuotedData’s Economic and Political Monthly Roundup December 2022
Economic and Political Monthly Roundup Investment companies | Monthly | December 2022 A collation of recent insights on markets and economies taken from the comments made by chairs and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage […]
-
11 Nov 2020 14 min read
International Biotechnology Trust – Healthy returns
International Biotechnology Trust (IBT) has delivered strong returns over the past 12 months, with the NAV up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The COVID-19 pandemic has focused attention on the sector as a number of companies search for effective treatments and vaccines. The […]
-
16 min read
International Biotechnology Trust – Healthy returns
International Biotechnology Trust (IBT) has delivered strong returns over the past year; its net asset value (NAV) is up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The COVID-19 pandemic has focused attention on the sector as a number of companies search for effective treatments and […]
-
16 min read
International Biotechnology Trust – Healthy returns
International Biotechnology Trust (IBT) has delivered strong returns over the past year, the NAV is up 30% over the year to date, well ahead of its benchmark, and wider national and global indices. The pandemic has focused attention on the sector as a number of companies search for effective treatments and vaccines. The sector has […]
-
07 May 2020 4 min read
QuotedData’s Economic Roundup – May 2020
Economic & Political Roundup Kindly sponsored by Allianz A collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or sell […]
-
07 Apr 2020 8 min read
QuotedData’s Investment Companies Roundup – April 2020
Investment Companies Roundup Kindly sponsored by Baillie Gifford and Aberdeen Standard Investments Table of contents New research In this issue Performance data Discounts and premiums Money in and out Major news stories Income Events Guide Appendix – Performance by sector full list New research Here is a list of research we published over March: An update note […]
-
02 Apr 2020 9 min read
International Biotechnology Trust – Trust in biotech
The biotechnology sector is proving to be relatively resilient in this COVID-19 related market sell-off. International Biotechnology Trust (IBT) adopts a conservative approach to investing in what can be a quite volatile, if rewarding, sector. It has fared better than competing funds in this environment. Some delay to drug development, testing programmes and product launches […]
-
9 min read
International Biotechnology Trust – Trust in biotech
Trust in biotech The biotechnology sector is proving to be relatively resilient in this COVID-19 related market sell-off. International Biotechnology Trust (IBT) adopts a conservative approach to investing in what can be a quite volatile, if rewarding, sector and has fared better than its peers in this environment. Some delay to drug development and testing […]
-
24 Jan 2020 20 min read
QuotedData’s Investment Companies Annual Review – 2019
In this issue The sector at the end of 2019 Performance data Performance by sector and fund Money in and out of the sector Money in and out of existing funds Money coming into existing funds Money going out of existing funds Liquidations, de-listings and trading cancellations Significant rating changes Major news stories Outlook for […]
-
06 Dec 2019 6 min read
QuotedData’s investment companies roundup – December 2019
Investment Companies Roundup Kindly sponsored by Baillie Gifford Table of contents New research In this issue Performance data Discounts and premiums Money in and out Income Events New research Here is a list of research we published over November: An initiation note on Henderson High Income “We have initiated coverage on Henderson High Income (HHI). Since […]
-
12 Nov 2019 1 min read
QuotedData’s economic roundup – November 2019
Economic & Political Roundup
-
15 Oct 2019 7 min read
Investment companies quarterly roundup – Third quarter 2019
Investment Companies Quarterly Roundup Kindly sponsored by Baillie Gifford New research Over the third quarter, we published notes on India Capital Growth, Jupiter Emerging & Frontier Income, Montanaro European Smaller Companies, JLEN Environmental Assets, Civitas Social Housing, JPMorgan Russian Securities, International Biotechnology Trust, Aberdeen Emerging Markets, Seneca Global Income & Growth, Standard Life Investments Property Income […]
-
19 Sep 2019 15 min read
International Biotechnology Trust – Healthy yield attracts investors
Healthy yield attracts investors The managers of International Biotechnology Trust (IBT) have focused its portfolio in oncology (cancer), diseases of the central nervous system and rare diseases – areas where pricing pressure on drugs and other therapies is less of an issue. This should cushion IBT as we approach election year in the US and […]
-
15 min read
International Biotechnology Trust – Healthy yield attracts investors
Healthy yield attracts investors The managers of International Biotechnology Trust (IBT) have focused its portfolio in oncology, diseases of the central nervous system and rare diseases – areas where pricing pressure is less of an issue. This should cushion the trust as we approach election year and (as is usually the case in the US […]
-
08 May 2019 4 min read
QuotedData’s economic roundup – May 2019
Economic & Political Roundup A collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or sell any of the […]
-
15 Apr 2019 6 min read
Quarterly Investment Companies Roundup – First Quarter 2019
Quarterly Investment Companies Roundup – First Quarter 2019 QuotedData news Through the first quarter of 2019, global equities largely clawed back the losses suffered over the final weeks of 2018. How much longer this ten-year bull market can sustain itself is the subject of much debate. US interest rate rises have stalled, reflecting growing cautiousness. Elsewhere, […]
-
08 Mar 2019 1 min read
International Biotechnology trust – Beating the odds
International Biotechnology Trust – Beating the odds Strategic positioning in mid-2018 helped International Biotechnology Trust (IBT) beat its benchmark over the past six months and close its discount to net asset value (NAV). This continued its outperformance of the US Nasdaq Biotechnology Index (NBI) over three and five years. Active management of the portfolio and […]
-
1 min read
International Biotechnology Trust – Beating the odds
International Biotechnology Trust – Beating the odds Strategic positioning in mid-2018 helped International Biotechnology Trust (IBT) beat its benchmark over the past six months and close its discount to NAV. This continued its outperformance of the US Nasdaq Biotechnology Index (NBI) over three and five years. Active management of the portfolio and an increased focus […]
-
25 Jan 2019 1 min read
QuotedData review of 2018 – Annual report investment companies
QuotedData review of 2018 – Annual report investment companies 2018 – the return of volatility A trade war, Brexit, US interest rate rises, slowing Chinese growth, a US government shutdown, a dispute over Italy’s budget, the Skripal poisonings, numerous elections – there was plenty to worry about in 2018. A last-minute dive left the US […]
-
13 Nov 2018 1 min read
QuotedData’s economic roundup – November 2018
QuotedData’s economic roundup – November 2018 is a collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or sell any […]
-
16 Oct 2018 2 min read
Quarterly Investment Companies Roundup – Third Quarter 2018
Quarterly Investment Companies Roundup – Third Quarter 2018 Global equities delivered positive returns over the third quarter of 2018. This was principally because of strength in the US market. Political uncertainty and concerns about global trade held back other regions. Generally, government bond yields rose over the quarter. The UK equity market fell as the Bank of […]
-
14 Sep 2018 1 min read
QuotedData’s investment companies roundup – September 2018
QuotedData’s investment companies roundup – September 2018 is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of August 2018. Kindly sponsored by Baillie Gifford. Money raised and returned in August GRIT Real Estate Income floated on the UK Stock Exchange in […]
-
19 Jul 2018 1 min read
International biotechnology – Outperformance and income
Under the leadership of its manager, Carl Harald Janson, International Biotechnology Trust (IBT) is building a track record of outperformance of both its benchmark, the Nasdaq Biotechnology Index and the average of its peer group (see page 13 of this note for the figures). The biotech sector, which IBT focuses on, benefits from long term structural growth drivers (listed on page 3) such as ageing populations in the developed world and an emerging middle class in developing markets. After a weak start in 2018, the Nasdaq Biotechnology Index has now recovered. The manager believes that the “American Patients First” document released by the US government on May 11 reduced investors’ concerns over drug pricing.
-
1 min read
International Biotechnology – Outperformance and income
International biotechnology – Outperformance and income Under the leadership of its manager, Carl Harald Janson, International Biotechnology Trust (IBT) is building a track record of outperformance of both its benchmark, the Nasdaq Biotechnology Index and the average of its peer group (see page 13 of this note for the figures). The biotech sector, which IBT focuses on, […]
-
11 Jul 2018 1 min read
QuotedData’s investment companies roundup – July 2018
QuotedData’s investment companies roundup – July 2018 is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of June 2018. Kindly sponsored by Baillie Gifford. July Investment Companies Roundup Money raised and returned in June Newcomer to the market, Yew Grove […]
-
11 May 2018 1 min read
QuotedData’s Economic round up – May 2018
QuotedData’s economic round up – May 2018 is a collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or […]
-
18 Apr 2018 1 min read
QuotedData’s Economic round up – April 2018
QuotedData’s economic round up – April 2018 is a collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or sell […]
-
11 Dec 2017 1 min read
QuotedData’s economic round up – December 2017
QuotedData’s economic round up – December 2017 – is a collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or […]
-
12 Jul 2017 2 min read
QuotedData investment companies roundup – July 2017
QuotedData investment companies roundup – July 2017 – is our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of June 2017. Kindly sponsored by Baillie Gifford. July Investment Companies Roundup Money raised in July Newly launched in June were […]
-
16 May 2017 1 min read
QuotedData’s economic round up – May 2017
QuotedData’s economic round up – May 2017 is a collation of recent insights on markets and economies taken from the comments made by chairmen and investment managers of investment companies – have a read and make your own minds up. Please remember that nothing in this note is designed to encourage you to buy or sell […]
-
07 Dec 2016 1 min read
QuotedData’s round up of views on the global economy – December 2016
QuotedData’s collation of recent insights on markets and economies taken from comments made by chairman and managers of investment companies. december-economic-and-political-roundup
-
08 Nov 2016 1 min read
QuotedData investment companies roundup – November 2016
Our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of October 2016. november-investment-companies-roundup-2
-
13 Oct 2016 1 min read
QuotedData investment companies roundup – October 2016
Our latest roundup of news; price, NAV and discount movements; flows in and out of the sector and report on full year dividends announced over the month of September 2016. october-investment-companies-roundup
News
-
10 Oct 2025 2 min read
Morning briefing: Saba lifts Smithson stake to 15%; biotech “on a tear” as $5.2bn Akero deal aids IBT and RTW; plus RSE, TMPL, CGT, ONWD, JADE
Saba Capital has increased its position in Smithson (SSON) to 15% from the 14.1% the activist hedge fund revealed a month ago. It now holds over 16.4m voting rights in Terry Smith’s £1.7bn global smaller companies investment trust on a 9% discount. International Biotechnology Trust (IBT) and RTW Biotech Opportunities have benefited from another acquisition […]
-
02 Oct 2025 2 min read
International Biotechnology commits £10m to Schroders Capital private equity funds
International Biotechnology Trust (IBT) is to expand its investments in unquoted companies under a partnership with Schroders Capital, the private markets arm of its fund manager Schroders. The £258m investment trust has committed to invest £10m, around 4% of its assets, in Schroders Capital funds focused on innovative, early-stage biotech companies. This is in addition […]
-
30 Sep 2025 3 min read
Morning briefing: UIL offers “ungenerous” buybacks before 2028 delisting; BAF crashes 82%; plus IBT, RTW, BRGE, BSRT, BASC, MVI
Annual results from UIL and Brown Advisory US Smaller Companies, dire interims from British & American, better half-year progress at Marwyn Value Investors and Baker Steel Resources, a fee cut at BlackRock Greater Europe and more beneficial M&A at RTW Biotech and International Biotechnology. UIL (UTL), a £286m split capital investment trust run by Utilico […]
-
23 Sep 2025 3 min read
Morning briefing: Pacific Horizon results disappoint; LAND upbeat; plus LABS, RLE, AUGM, IBT, RTW, WKOF & AEET
Pacific Horizon (PHI), the £618m pan-Asia trust run by Roderick Snell and Ben Durrant at Baillie Gifford, continued to underperform in the second half of its financial year, annual results show. As a result, over the year to 31 July the underlying total return in net asset value (NAV) was 8.3%, below the 17.1% increase […]
-
19 Sep 2025 2 min read
Morning briefing: Knockout bid for 89Bio boosts International Biotechnology; plus MCT, NCYF, FGEN & INOV
International Biotechnology Trust enjoys another premium takeover for one of its companies; there are results from Middlefield Canadian, New City High Yield and Schroders Capital Global Innovation; and Foresight Environmental Infrastructure clears its discontinuation vote. International Biotechnology Trust (IBT) says 89Bio, a US Nasdaq-listed company accounting for 0.5% of its £230m portfolio, yesterday received a […]
-
22 Jul 2025 2 min read
QuotedData’s morning briefing 22 July: ICGT, ESCT, IBT, MMIT, VNH, MIGO, JII, SDP, SEC, JPEL & RGL
ICG Enterprise nets £22m from the sale of VR software provider Datasite and European Smaller Companies, International Biotechnology, Mobius and Vietnam Holding all report good gains for June. ICG Enterprise Trust (ICGT) has sold its co-investment in Datasite, a software provider focused on virtual data rooms that at 31 January was its fourth largest company exposure […]
-
18 Jul 2025 3 min read
Which trust dividends have grown faster than inflation?
Inflation is creeping back up again. The annual rate of inflation as measured by the Consumer Price Index (CPI) is now 3.6% or, to look at it another way, prices are almost 28% higher than they were five years ago. If we were using the old RPI measure, those figures would be 4.4% and 38%. […]
-
1 min read
Biotech Growth looks “susceptible” to merger approach after continuation vote shows dissent
Biotech Growth (BIOG) passed its five-yearly continuation vote yesterday with 76.7% of votes in favour, but with over 23% of votes cast against the resolution, the £198m company could be vulnerable to consolidation in the sector, broker Deutsche Numis believes. Shares in the global biotech fund have slumped around 40% since the last vote in […]
-
20 Jun 2025 4 min read
The biotech bust: a case study in hype, hubris but now hope
The rout in the healthcare sector shows no sign of abating. Even during the recent market weakness, investors haven’t appreciated its defensive qualities, but have instead focused on the potential disruption to US healthcare from an unpredictable new administration. However, contrarian investors may spot opportunities in the gloom. The MSCI World Healthcare index is down […]
-
14 Jan 2025 2 min read
QuotedData’s morning briefing 14 January 2025 – IBT, HRI, RTW, TMI, FP, CBA
In QuotedData’s morning briefing 14 January 2025: International Biotechnology trust (IBT) has announced Johnson and Johnson’s acquisition of Intra-Cellular Therapies (ITCI) for $132 per share, representing a premium of approximately 40% to ITCI’s closing share price on 10 January 2025. ITCI is IBT’s largest shareholding, representing 7.14% of IBT’s NAV as at 10 January 2025. […]
-
05 Nov 2024 3 min read
International Biotechnology Trust sees 15.9% return through 2024
International Biotechnology Trust (IBT) announced its annual results for the year ended 31 August 2024. The company delivered a NAV total return of 15.9%, outperforming the reference index which returned 15.3%. Despite the strong performance the discount continued to widen during the year, leading to a share price total return per share of 10.3%. The […]
-
19 Jul 2024 4 min read
Time to inject some healthcare into your portfolio?
The healthcare and biotechnology sector has some natural tailwinds: ageing populations, rising emerging market wealth, innovation and rising healthcare utilisation. However, while pharmaceutical companies have been stable, biotechnology has been hit by poor sentiment and rising interest rates. Nevertheless, there are signs of recovery. The sector is diverse. Funds such as Polar Capital Global Healthcare […]
-
08 May 2024 1 min read
QuotedData’s morning briefing 8 May 2023 – IBT, WKP/CAL
In QuotedData’s morning briefing 8 May 2023: International Biotechnology Trust (IBT) announced its results for the six month period ended 29 February 2024. The company saw a 11.2% NAV total return per share, substantially outperforming the Reference Index which rose by 8.2%. Notable contributions came from Vera Therapeutics, an autoimmune company which is a top […]
-
20 Nov 2023 1 min read
QuotedData’s morning briefing 20 November 2023 – SSIT, INOV, IBT, USF, UKCM
In QuotedData’s morning briefing 20 November 2023: Seraphim Space Investment Trust (SSIT) has released its Q1 update. Highlights include a further £4.1m, invested in two projects over the quarter. Portfolio value increased to £199.9m up £12.4m, due to a combination of additional investments, unrealised fair value net gains and an unrealised FX gain. The main […]
-
07 Nov 2023 2 min read
Another steady year for International Biotechnology
International Biotechnology Trust (IBT) announced its results for the year ended 31 August 2023. The share price total return rose by 3% over the financial year to the end of August 2023, while the benchmark NASDAQ Biotechnology Index (NBI) fell by 1.4% over the same period. The company’s Net Asset Value rose by 2.7%. Most of […]
-
03 Aug 2023 3 min read
Schroders takes on International Biotechnology
International Biotechnology Trust has decided to appoint Schroder Unit Trusts Limited as its fund manager and AIFM. Shareholders had told the board that they wanted continuity of the company’s investment approach under the existing investment management team and to retain the dividend policy. Ailsa Craig and Marek Poszepczynski (who have been lead managers on the […]
-
03 May 2023 3 min read
International Biotech continues to impress
International Biotech (IBT) announced its half-yearly report for the year ended 28 Feb 2023. The company’s share price was up 8.0% over the six month period, well ahead of the Nasdaq Biotechnology Index (NBI), which had a total return of 1.8%. The company’s Net Asset Value total return over the period was 6.1%. Over three […]
-
14 Mar 2023 1 min read
Great result for International Biotech as Seagen gets bid
International Biotechnology Trust is in line for a big jump in its net asset value as its largest holding has been bid for. The trust owned 200,000 shares in Seagen Inc on 10 March, valued at $34.5m, making it the largest position in the trust, accounting for about 10.2% of the portfolio. On 13 March […]
-
17 Feb 2023 1 min read
QuotedData’s weekly news show 17th February 2023
Thank you to everyone that listened in today, whether you watched the Zoom live, on Facebook or on YouTube. In this week’s show, James Carthew covered the week’s top stories: • International Biotechnology (0:52) • abrdn Smaller Companies Income (6:26) This week’s interview was with James Dow from The Scottish American Investment Company – watch […]
-
13 Feb 2023 2 min read
International Biotechnology manager quits
SV Health (manager and AIFM for International Biotechnology) has informed the trust that it wishes to focus on its core healthcare venture business – quitting the job of managing the fund. Ailsa Craig and Marek Poszepczynski, the current lead managers, want to stay on in the role. The board has agreed that they will continue […]
-
13 Dec 2022 1 min read
QuotedData’s morning briefing 13 December 2022
In QuotedData’s morning briefing 13 December 2022: HgCapital Trust (HGT) is selling its stake in Transporeon, a leading cloud-based logistics and transportation management software platform, to Trimble as part of a transaction that values the whole of that business at an enterprise value of €1.88bn. The trust’s share of the proceeds is about £107.8m. The […]
-
01 Nov 2022 3 min read
Weak market holds back International Biotechnology
International Biotechnology reports a -6.9% return on NAV and -6.4% return to shareholders for the year ended 31 August 2022. However, it beat its performance benchmark, the NASDAQ Biotechnology Index (NBI), which returned -13.8%. This helped the trust claw back some of its underperformance relative to its benchmark over the past five years so that, […]
-
22 Jul 2022 3 min read
QD view – Is the tide finally turning for biotech?
In early 2021, it looked like the pandemic had been a breakthrough moment for the biotechnology sector. The sector had been critical in the development of Covid-19 vaccines, using new and innovation gene sequencing, while developments in oncology promised a treatment revolution. Share prices were riding high and specialist investment trusts had enjoyed two years […]
-
04 May 2022 2 min read
QuotedData’s morning briefing 4 May 2022
Rockwood Realisation (RKW) has changed its name to Rockwood Strategic following a turnaround in its plans and the decision to remain an investment trust, as we have previously reported. The group has also launched the Rockwood Strategic Investment Advisory Group (IAG) whose members offer the benefits of cumulatively over 150 years of relevant investment experience. […]
-
31 Dec 2021 1 min read
QuotedData’s morning briefing 31 December 2021
In QuotedData’s morning briefing 31 December 2021: International Biotechnology Trust (IBT) will invest in SV Health Investors (the manager)’s forthcoming biotechnology focused private fund, SV Biotech Crossover Opportunities Fund LP. The trust tries to keep its exposure to unquoted stocks between 5% and 15% of its portfolio. Murray International (MYI) says that, with effect from […]
-
01 Nov 2021 4 min read
Tough year for International Biotechnology but confidence remains
Tough year for International Biotechnology but confidence remains – International Biotechnology (IBT) has published its annual results for the year to 31 August 2021. During this time, the company’s NAV per share and share price returned 9.8% and 3.8% respectively whilst the Nasdaq Biotechnology Index returned 22.8%. The board said while this is a disappointing […]
-
05 Jul 2021 3 min read
QD view – Volatility remains hallmark of biotech in first half
Essa Pharmaceutials (Nasdaq: EPIX) and Moderna (MRNA) may have been the top performers within Swiss investment company BB Biotech’s (SIX:BION) 34-strong portfolio in the first half, sporting stock price rises of 137% and 124% respectively, but these gains are modest by comparison with some of the ones from within the wider world of biotech investing. […]
-
26 Apr 2021 1 min read
QuotedData’s morning briefing 26 April 2021
In QuotedData’s morning briefing 26 April 2021 – International Biotechnology Trust’s (IBT’s) interim results to 28 February 2021 saw the NAV per share return 6.9%. On the management side, Carl Harald Janson decided to step back from his role as lead manager (he will remain involved with IBT as a senior advisor) and Kate Bingham was welcomed back […]
-
15 Mar 2021 2 min read
QuotedData’s morning briefing 15 March 2021
In QuotedData’s morning briefing 15 March 2021 – International Biotechnology Trust’s (IBT’s) board and its manager, SV Health Investors, announced that Carl Harald Janson has decided to step back from his role as lead manager after seven at the helm. Lead responsibility for portfolio management will transition to Ailsa Craig and Marek Poszepczynski and the board […]
-
16 Dec 2020 1 min read
QuotedData’s morning briefing 16 December 2020
In QuotedData’s morning briefing 16 December 2020: Ruffer backs Bitcoin – in a surprise move, the trust says “One recent addition, via one of the specialist managers appointed within the Ruffer Multi-Strategies Fund, has been bitcoin. This is primarily a defensive move, one made in November after reducing the company’s exposure to gold. The exposure to […]
-
19 Nov 2020 1 min read
QuotedData’s morning briefing 19 November 2020
In QuotedData’s morning briefing 19 November 2020: International Biotechnology reports that an uplift in the value of its stake in SV Fund VI has added $4.8m (£4.0m) or 9.1p per share to its NAV. Octopus Renewables Infrastructure Trust has secured a committed £150m revolving credit facility (RCF) from a group of five lenders. The RCF, provided […]
-
02 Nov 2020 3 min read
Its been a strong year for International Biotechnology Trust
International Biotechnology Trust’s (IBT) has reported full-year results, to 31 August 2020. IBT’s NAV per share and share price returned 22.4% and 18.7%, whilst the NASDAQ Biotechnology index (NBI) returned 20.6% (to 31 August 2020) and the FTSE All-Share index returned -12.6% (to 28 August 2020). The table below summarises IBT’s cumulative total return performance over […]
-
23 Oct 2020 2 min read
QD view – US election, why worry?
Election day is edging closer in the US and the rhetoric is ramping up. We managed to catch up with Dean Orrico, the manager of Middlefield Canadian Income Fund (the subject of last week’s article) in the weekly interview and he reiterated his observation that Biden is likely to win the Presidential election. The more […]
-
19 May 2020 1 min read
Two new directors for IBT
Two new directors for IBT – International Biotechnology Trust has two new non-executive directors. Kate Cornish-Bowden and Patrick Magee take up their roles today. They will replace two existing directors. John Aston intends to retire from the Board at the conclusion of the AGM to be held in December 2020 and it is expected that Dr […]
-
27 Apr 2020 2 min read
International Biotechnology Trust says sector’s long-term fundamentals remain undiminished
International Biotechnology Trust’s (IBT) has reported interim results, to 29 February 2020. The pandemic’s sustained impact on financials markets began in March, so the impact on IBT’s portfolio over this results period, was negligible. Over the interim period, the company’s NAV per share returned 3.6%. By comparison, the NASDAQ biotechnology index (NBI) returned 6.0% and […]
-
24 Apr 2020 2 min read
We talk to SV Health Investors about COVID-19
This week, I was fortunate to catch up with SV Health Investors, managers of the unquoted investments within International Biotechnology Trust. The discussion centred on COVID-19 and how it is affecting the healthcare industry. One UK-based member of the team, Kate Bingham, is a member of the UK Government’s Vaccine Taskforce. The majority of the […]
-
10 Feb 2020 1 min read
QuotedData’s other news 10 February 2020
In QuotedData’s other news 10 February 2020 – Intu Properties (INTU) confirmed that further to press speculation, it is engaged in discussions with shareholders and new investors, in relation to a proposed equity raise alongside the company’s full year results at the end of February. INTU says it will make further announcements in due course, […]
-
10 Jan 2020 2 min read
Biotech Growth tops bio-trust league with 47% NAV rise – updated
Biotech Growth tops bio-trust league with 47% NAV rise – Orbimed-managed Biotech Growth Trust (BIOG) recorded the rise 47% rise in NAV in 2019, representing the best performance of the 14 specialist biotech/pharma closed end investment vehicles monitored by Marten & Co. Biotech Growth’s rise in NAV was more than double that of the benchmark […]
-
29 Oct 2019 1 min read
Unquoteds outperform for International Biotechnology Trust
Unquoteds outperform for International Biotechnology Trust – International Biotechnology Trust (IBT) has reported annual results to 31 August 2019. The majority of IBT’s portfolio holdings are based in the US. Headline results: Share price (2.1%) NAV (6.8%) NASDAQ Biotechnology Index (NBI) (9.8%) FTSE All-Share Index: +0.4% Quoted portfolio outperformed benchmark over challenging period IBT’s quoted […]
-
09 Sep 2019 2 min read
Acadia stock surges 65% on positive trial result in dementia psychosis
Acadia stock surges 65% on positive trial result in dementia psychosis – US biotech Acadia Pharmaceuticals (Nasdaq: ACAD) saw its stock jump 65% today on the back of a positive result in its “Harmony” Phase III study of Nuplazid (pimavanserin) for dementia-related psychosis. The company reported that the study met its primary endpoint, demonstrating a […]
-
21 Mar 2019 1 min read
Biogen Alzheimer’s failure drags down Biotech Growth
Biogen Alzheimer’s failure drags down Biotech Growth – Biogen, a key holding in Biotech Growth Trust and a component of most other biotech and healthcare portfolios, has lost a third of its value after trials of an Alzheimer’s drug failed to show any benefit. Biogen and its partner, Japanese drugmaker Eisai, said they would stop […]
-
30 Oct 2018 4 min read
International Biotechnology benefits from narrowing discount
International Biotechnology benefits from narrowing discount – International Biotechnology has reported that, over the year ended 31 August 2018, its NAV laggeded the NASDAQ Biotechnology Index (NBI) a little, returning 8.6% versus the NBI return of 10.1%. A narrowing discount meant that shareholders saw a total return of 13.7%, however. The biotech sector outperformed the UK equity market over […]
-
03 Sep 2018 2 min read
IBT-investee Sangamo set to disclose gene edited drug data
IBT-investee Sangamo set to disclose gene edited drug data US biotech Sangamo Therapeutics (Nasdaq: SGMO), a mid portfolio but recently enlarged holding for the UK-listed International Biotech Trust (IBT), is set to report the first clinical data from its SB-913 in vivo genome edited therapeutic for Hunter syndrome, at a scientific conference later this week. Sangamo will […]
-
30 Aug 2018 2 min read
IP Group-backed Genomics raises £25m in a Series B
IP Group-backed Genomics raises £25m in a Series B Genomics plc, a University of Oxford spin-out backed by UK-based healthcare/tech VC investor IP Group (LSE: IPO), has closed a £25.0m Series B financing round led by the major US biotech, Vertex Pharmaceuticals. Woodford Investment Management – manager of the Woodford Patient Capital Trust (WPCT) – Invesco Perpetual, Oxford […]
-
16 Aug 2018 2 min read
IBT adds to Celgene, reduces Neurocrine in July rejig
IBT adds to Celgene, reduces Neurocrine in July rejig International Biotechnology Trust (IBT) appears to have boosted its shareholding in Celgene – which has risen by one place and ~ two NAV percentage points to become its top investee company, as part of a rejig of its largest investments in July. According to the trust’s latest […]
-
13 Aug 2018 1 min read
FDA sets Feb target review date for IBT-backed Stemline Therapeutics
FDA sets Feb target review date for IBT-backed Stemline Therapeutics The US FDA has accepted Stemline Therapeutics (Nasdaq:STML)’s filing for Elzonris (tagraxofusp) for review for blastic plasmacytoid dendritic cell neoplasm (BPDCN), an extremely rare haematological cancer, and with priority review, the agency has set itself a PDUFA target action date of 21 February 2019 – although […]
-
06 Aug 2018 1 min read
IBT backed Regeneron teams up with Bluebird on T cell cancer therapies
IBT backed Regeneron teams up with Bluebird on T cell cancer therapies US top tier biotech Regeneron Pharmaceuticals (NASDAQ: REGN) is to make a $100m equity investment at a 59% premium in the gene therapy pioneer Bluebird Bio, as part of a newly established collaboration to develop and commercialise novel immune cell therapies for cancer. Regeneron is […]
-
03 Aug 2018 1 min read
Tekla Healthcare top specialist fund performer in July
Tekla Healthcare top specialist fund performer in July Tekla Healthcare Opportunities, a US closed end fund that invests largely in US large cap pharma and biotech, saw the best investment performance of the 14 specialist biotech specialist investors monitored by Marten & Co, in terms of its sterling-adjusted NAV performance for the month of July. Switzerland’s BB […]
-
2 min read
Trust favourite Neurocrine’s shares rise on strong Ingrezza report
Trust favourite Neurocrine’s shares rise on strong Ingrezza report Neurocrine Biosciences (Nasdaq: NBIX), the US biotech that is the largest single holding for International Biotechnology Trust (IBT, 5.5% of NAV) and second largest for BB Biotech (BBB.S, 8.9% of NAV), has seen its share rise by more than 15% this week on the back of a strong […]
-
20 Jul 2018 1 min read
FDA approves BB Biotech backed Agios’ AML drug Tibsovo
FDA approves BB Biotech backed Agios’ AML drug Tibsovo Agios Pharmaceuticals (NASDAQ:AGIO), a top 10 holding for Switzerland’s BB Biotech (BBB), has received US FDA approval for Tibsovo for relapsed or refractory acute myeloid leukaemia (r/r AML) with a specific IDH1 mutation. Agios, which has seen its shares rise by ~50% this year, accounted for […]
-
12 Jul 2018 2 min read
EC approves Ionis’ amyloidosis drug
EC approves Ionis’ amyloidosis drug Ionis Pharmaceuticals (Nasdaq: IONS) has received marketing authorisation from the European Commission for Tegsedi (inotersen), its RNA-targeted therapeutic for stage 1 or 2 polyneuropathy in adults with hereditary transthyretin amyloidosis (hATTR). This is the first approval for the drug and unusually EU approval has come through ahead of the US, with the outcome of […]
-
10 Jul 2018 2 min read
Celgene claims win for luspatercept in Believe trial
Celgene claims win for luspatercept in Believe trial Specialist trust favourite Celgene (Nasdaq: CELG) has reported positive result in a Phase III trial with the drug candidate luspatercept for treatment of anaemia associated with beta-thalassemia. This follows the company’s success in the Medalist Phase III trial win with the same drug in anaemia associated with myelodysplastic syndrome (MDS). The unambiguous […]
-
29 Jun 2018 2 min read
Trust favourite Celgene claims win in Medalist trial
Trust favourite Celgene claims win in Medalist trial US biotech and specialist trust favourite Celgene (Nasdaq: CELG) has reported a positive result in a closely-watched Phase III trial that was being seen as a key step necessary in its rehabilitation with investors. The trial was of the drug candidate luspatercept for treatment of anaemia associated with a type […]
-
25 Jun 2018 2 min read
IBT favourite Array updates trial results ahead of key FDA decision
IBT favourite Array updates trial results ahead of key FDA decision Array Biopharma (ARRY), a top ten holding for LSE-listed International Biotechnology Trust (IBT), has reported positive results from a safety lead-in phase of a pivotal trial of a triplet therapy comprising two of its drugs – binimetinib and encorafenib – with Merck KGaA’s Erbutix in BRAF mutant […]
-
30 May 2018 2 min read
FDA fast track review for trust-backed Sage Therapeutics
FDA fast track review for trust-backed Sage Therapeutics Sage Therapeutics (Nasdaq: SAGE), a high conviction idea for two of the biotech sector specialist investment trusts, has confirmed that the US FDA has accepted the NDA filing for its lead product, brexanolone IV for treatment of postpartum (post natal) depression (PPD), and granted the application priority review status. NDA […]
-
29 May 2018 2 min read
Trust favourite Genmab hit by trial setback
Trust favourite Genmab hit by trial setback Denmark’s Genmab, a widely-held stock among the sector specialist investment trusts, has suffered a major setback in the past week with failure/termination of studies involving its lead product Darzalex, which is sold by Johnson & Johnson. The studies were both aimed at expanding the range of uses of Darzalex, […]
-
02 May 2018 1 min read
Trust stalwart Regeneron cuts Praluent price
Trust stalwart Regeneron cuts Praluent price Investment trust stalwart Regeneron Pharmaceuticals (NASDAQ: REGN) and its partner Sanofi yesterday announced a deal with Express Scripts, under which they will substantially lower the net price of Praluent in exchange for exclusive coverage on the US pharmacy benefit manager’s national formulary. The move deals a blow to rival Amgen, […]
-
30 Apr 2018 1 min read
IBT tops up on Shire and Celgene in March
IBT tops up Shire and Celgene in March SV Health-managed International Biotech Trust (IBT) recorded a 3.2% fall in NAV in March, slightly under-performing the Nasdaq Biotechnology Index, which was down by 2.9% in sterling terms. The manager reported that the main positive contributors of NAV in the month were Shire Pharmaceuticals, Nektar Therapeutics and […]
-
23 Mar 2018 2 min read
IBT takes profits on Nektar, buys Array
IBT takes profits on Nektar, buys Array SV Health-managed International Biotech Trust (IBT) saw a 2.2% fall in NAV in February, beating the 2.6% decline reported for the sterling-adjusted value of the benchmark Nasdaq biotechnology index by a small margin, one of only a handful of sector specialist trusts to do so. The main positive […]
-
02 Mar 2018 2 min read
Swiss trusts top performers among bio sector specialists in Feb
Swiss trusts top performers among bio sector specialists in Feb – Switzerland’s HBM Healthcare Investments (HBMN.S) and BB Biotech (BBB.S) were the best performing biotech/pharma specialist investment trusts in February and indeed were the only ones of the 13 monitored by Marten & Co to have recorded any increase in NAV (in sterling terms) in the month. However, […]
-
27 Feb 2018 2 min read
International Biotech records modest rise in NAV in Jan
International Biotech records modest rise in NAV in Jan SV Health-managed International Biotech Trust (IBT) reported a 1.4% rise in NAV and saw a 0.4% rise in its share price in January, according to its latest monthly update. The outcome was a little under the 2% rise in the sterling adjusted value of the NASDAQ […]
-
15 Feb 2018 2 min read
Trust favourite Biogen hit by AD trial rejig
Trust favourite Biogen hit by AD trial rejig – Shares in Biogen, the neurology-focused US biotech giant and a key holding for many of the sector specialist investment trusts, fell by more than 6% yesterday on heightened concerns over a decision to expand patient enrolment in its two large Phase III trials of aducanumab for […]
-
14 Feb 2018 3 min read
IBT key beneficiary of massive BMS-Nektar deal
IBT key beneficiary of massive BMS-Nektar deal – International Biotech Trust (IBT) looks set to be the main investment trust beneficiary of the massive deal signed today between Bristol-Myers Squibb (BMS) and Nektar Therapeutics covering what had hitherto been – albeit briefly – the industry’s hottest un-partnered cancer drug, NKTR-214. Nektar is the third largest shareholding for […]
-
13 Feb 2018 1 min read
Key trust holding Vertex gains US approval for new CF combo
Key trust holding Vertex gains US approval for new CF combo Vertex Pharmaceuticals, a leading US biotech specialising in cystic fibrosis (CF) and core holding for most of the sector’s collective investment vehicles, yesterday reported the US FDA approval of Symdeko, its new combination containing tezacaftor/ivacaftor for CF in patients aged 12 and over who are […]
-
09 Feb 2018 2 min read
Swiss biotech trusts resilient after recent sell-off
Swiss biotech trusts resilient after recent sell-off – Swiss-listed biotech investment trusts, HBM Healthcare Investments (HBMN.S) and BB Biotech (BBB.S), have fared by far the best among all the sector specialist closed-end collective vehicles in the wake of the global market sell-off in recent days. All 13 trusts in the group monitored by Marten & Co have seen a fall […]
-
23 Jan 2018 2 min read
HBM Healthcare tops biotech trust league in 2017
HBM Healthcare tops biotech trust league in 2017 Swiss-listed HBM Healthcare Investments (HBMN.S) can claim to have been the best performing biotech-specialist closed-end fund in 2017, according to an analysis by Marten & Co. The CHF1.1bn trust run by Swiss healthcare investment specialist HBM saw its share price rise from CHF99 to CHF134 last year […]
-
02 Jan 2018 2 min read
Key guidance expected for biotech trust favourite Biogen
Key guidance expected for biotech trust favourite Biogen Biogen, the neurology-focused US biotech giant and a key holding for several of the UK’s sector specialist investment trusts, will provide a closely-watched update for investors at next week’s JP Morgan Healthcare conference that could be critical to its 2018 outlook. Biogen’s CEO will present at the conference, […]
-
18 Dec 2017 1 min read
Investment Trust Insider on Biotech
Investment Trust Insider on Biotech – inspired by the launch of our biotech news service on QuotedData, I wrote something for Citywire that looks at some of the exciting stories that have been published just in the last couple of weeks. James Carthew: biotech boom boosts generalist trusts This week I am returning to the […]
-
11 Dec 2017 1 min read
Gilead reassures with CAR-T therapy durability data
Gilead reassures with CAR-T therapy durability data – Leading US biotech and investment company favourite Gilead Sciences has reassured investors with an important clinical trial update for its high profile cancer therapy Yescarta, which was obtained via the $12bn purchase of Kite Pharmaceuticals earlier this year. Longer follow-up data from 108 advanced lymphoma patients treated with Yescarta […]
-
08 Dec 2017 1 min read
Gilead acquires Cell Design Labs to bolster CAR-T presence
Gilead acquires Cell Design Labs to bolster CAR-T presence Leading US biotech Gilead Sciences is to acquire privately-held Cell Design Labs in a structured buy out valued at to $567m, including the 12.2% shareholding it already holds as a result of its $12bn acquisition of Kite Pharmaceuticals earlier this year. The Kite deal propelled Gilead […]
-
07 Dec 2017 1 min read
FDA OK for Alexion’s Soliris in myasthenia gravis
FDA OK for Alexion’s Soliris in myasthenia gravis US approval for Alexion’s complement inhibitor Soliris in anti-acetylcholine receptor antibody-positive generalised myasthenia gravis could double the market for a product that is already selling $3bn/year, if some of the most optimistic sell-siders are to be believed. Soliris, which is famously one of, if not the, most […]
-
03 Nov 2017 3 min read
International Biotechnology beats benchmark on strong listed portfolio performance
International Biotechnology beats benchmark on strong listed portfolio performance – In the year ended 31 August 2017, International Biotechnology Trust’s NAV rose from 575.1p to 672.9p, including a significant currency gain, equivalent to 14.4 pence per share. The NAV returned 20.9% in. Over the same period, the Shareholders total return was 30.5%. This compares to a rise […]
-
03 May 2017 2 min read
14th consecutive year of outperformance for BlackRock Smaller
For fourteen consecutive years BlackRock Smaller Companies has outperformed its benchmark and increased its dividend. Over that period, the NAV has grown nearly ten-fold whereas the benchmark has almost quadrupled. The compound annual increase in dividends paid over the past five years has been 20% per annum. During the year to 28 February 2017, the NAV increased […]
-
07 Feb 2017 1 min read
All trust sectors bar one made money in ’16
UK Smaller Companies was the only investment sector to lose money in 2016 despite a turbulent political and economic landscape, new research has revealed. See more here
-
06 Feb 2017 1 min read
14 investment trusts for income and growth in 2017
Investors looking forward to a period of calm in 2017 might be disappointed, but David Prosser has the trusts experts are backing to navigate further storms. Having just been through a year of unprecedented political upheaval that sent financial markets spinning, many investors will be assuming 2017 cannot possibly be so tumultuous. The reality, however, […]
-
30 Nov 2016 1 min read
Lazard World Trust discount narrows
Lazard World Trust Fund’s net asset value rose 5.9% on a total return basis, compared with the gain of 6.2% of the MSCI All Country World ex-USA Index during the six-month period ended 30 September 2016. The Fund’s share price, as traded on the London Stock Exchange, was up 8.6% (dividends reinvested) as the discount narrowed. […]
-
07 Nov 2016 3 min read
Takeovers help International Biotechnology beat its benchmark
International Biotechnology Trust outperformed the Nasdaq Biotech Index over the year to the end of August 2016 as the fund’s NAV return was -1.7% against -3.8% for the index. Unfortunately, the discount widened from 5.7% to 13.5% and therefore the return to shareholders was -9.8%. Quoted portfolio The quoted portfolio outperformed the NBI by 1.1% in the […]
-
17 Oct 2016 1 min read
Japan investment trusts lure hungry investors
Japan investment trusts have stormed the charts over the past month, with investors showing renewed confidence in the performance of Japanese corporates. read more here
-
09 Sep 2016 2 min read
International Biotech to pay dividend
The Board of International Biotechnology Trust has announced two proposals which it believes will be of benefit to shareholders and potential investors. These include the introduction of dividend payments and amendments to International Biotechnology Trust’s investment policy to allow it to invest in unquoted funds. Both proposals will be subject to shareholder approval at a […]
-
14 Jul 2016 2 min read
Lazard World Trust gets mixed results from China
Lazard World Trust Fund reports that, for the year ended March 31st 2016, the fund’s Net Asset Value per share at the year-end was US$ 4.17 representing a total return of minus 8.04% since the prior year end. The fund’s benchmark, the MSCI All Country World Index, declined 4.3% over the same period while the fund’s reference […]
-
10 Jun 2016 1 min read
Biotech And Healthcare Funds Enjoyed Small Rally In May – QuotedData
LONDON (Alliance News) – British & American Investment Trust PLC, Biotech Growth Trust PLC, and International Biotechnology Trust PLC were among the best-performing London-listed investment companies in May, according to research firm QuotedData, which said there was a “small rally” in the biotech and healthcare sector that month. You can read the rest of the […]
-
18 Apr 2016 1 min read
Best and worst performing investment trusts: Unloved commodity, Brazil and Russia funds finally come good
Recovery in commodity prices has boosted investment trusts specialising in the sector Investors also hoping for Brazil revival if leader Dilma Rousseff is ousted Biotech and healthcare hit by fears Democrat party will squeeze drug prices if they win the US http://www.thisismoney.co.uk/money/investing/article-3542148/Unloved-commodity-Brazil-Russia-funds-finally-come-good.html
-
2 min read
International Biotechnology Trust held back by Chimerix
During the six months to 29 February 2016, International Biotechnology’s NAV fell by 17.7% from 585.1p to 481.7p. Over the same period, the share price fell by 22.9% from 551.5p to 425.0p. This compares with a decline in the NASDAQ Biotechnology Index (NBI) of 18.0% and a fall in the FTSE All-Share Index of 1.2%. The discount closed […]
-
21 Mar 2016 3 min read
All change again for Jupiter Global
Jupiter Global’s board has decided to seek shareholders’ approval for a change in both the company’s investment strategy and name with effect from the general meeting of shareholders which has been convened for next month. These changes are the subject of a circular which has been posted alongside the Half Year report. This is an important […]
-
05 Nov 2015 2 min read
International Biotech reports impressive results
International Biotechnology Trust has announced results for the year ended 31 August 2015. Over this period the NAV return was 48.2% which compares very favourably to the return on IBT’s benchmark, NASDAQ Biotechnology Index, which returned 33.6%. The share price did even better as the discount narrowed from 20.5% to 6.0% and shareholders got a return […]
-
14 Apr 2015 1 min read
M&A activity produces great results for International Biotechnology
International Biotechnology’s results for the six months ended 28 February 2015 are out and they show that the fund had a fantastic time with the net asset value rising by 44.5%. The share price was up 57.4% over this period as they bought back 23% of the company to cut the discount from 21.5% to […]
-
13 Jan 2015 1 min read
International Biotech making 15x its money on Convergence
International Biotech is part owner of an unquoted UK biotech stock, Convergence Pharmaceuticals, that is being acquired by Biogen Idec. At the purchase price of $675m, International Biotech’s stake is worth £6.8m. This compares to the £442,000 valuation of the company in International Biotech’s accounts. For now though International Biotech is writing up the value […]
-
26 Nov 2014 1 min read
Mixed results for World Trust Fund
WTR : Mixed results for World Trust Fund World Trust Fund reports that over the six months ended 30 September 2014 its fully diluted net asset value in US dollar terms fell 0.2%, lagging the MSCI All Country World Index which rose 2.6%, though ahead of the MSCI All Country World ex-US Index which fell 0.5%. […]
-
03 Nov 2014 1 min read
International Biotech fee cut
IBT : International Biotech fee cut International Biotechnology Trust has announced its results for the year that ended on 31 August 2014. They show the net asset value rising by 26.4% which lags the return on the NASDAQ Biotechnology Index which returned 33.2% in Sterling terms. Shareholders were impacted by a widening of IBT’s discount […]
Upcoming Events
Videos
In The Press
-
07 Apr 2025 1 min read
Investment trust insider on Trump’s tariff effects
A couple of weeks ago, I was discussing the possible impact of tariffs on Vietnam. If you recall, the managers of VinaCapital Vietnam Opportunity Fund (VOF) were fairly sanguine about the prospect, reasoning that the US would see Vietnam as an ally in the region and recognise that it was making an effort to address […]
-
03 Mar 2025 1 min read
Investment trust insider compares Biotech Growth and International Biotechnology
Investment trust insider compares Biotech Growth and International Biotechnology – James Carthew: Am I too late to switch biotech trust? Our columnist is disappointed by Biotech Growth Trust’s returns over the past decade and wonders whether rival International Biotechnology is now more compelling. Biotech Growth Trust (BIOG) has been on a rollercoaster ride over the […]
-
14 May 2024 2 min read
Healthcare funds roar back to life
by Dave Baxter, Investors Chronicle, May 14, 2024: Areas like biotech can be racy at the best of times and especially vulnerable to shifting investor whims. That much has become evident in recent years: the average investment trust in the AIC’s Biotechnology and Healthcare sector made a whopping 21 per cent share price total return […]
-
11 Dec 2023 1 min read
Have enhanced income funds and trusts delivered for investors?
by Cherry Reynard from interactive investor, 5th December 2023: At a time when income is abundant, “enhanced income” strategies have been a surprise hit in 2023. The largest actively managed ETF in the world is now the JPM Equity Premium fund, a covered call strategy with $30 billon (£23.7 billion) in assets, while Morningstar identified […]
-
20 Nov 2023 1 min read
Investment trust insider on RTW Biotech
Investment trust insider on RTW Biotech – James Carthew: RTW Biotech will succeed with or without Arix I was singing the praises of capital markets days last week. Last Tuesday, I managed to get along to one held by RTW Biotech Opportunities (RTW). The day was planned some time ago, but the timing was great […]
-
17 Nov 2023 1 min read
The IC investment trust income portfolios: our changes for the year ahead
by Dave Baxter, Investors’ Chronicle, November 16, 2023: The idea that investment trusts provide a reliable income through thick and thin has truly been tested in recent years, from the UK equity dividend suspensions of 2020 to the bond sell off seen over the last two years and the consequences that has had for yield-rich […]
-
06 Oct 2023 1 min read
Past the peak
Faith Glasgow, AIC Compass Magazine, October 2023: Interest rate rises took a breather in September, as the Bank of England narrowly opted to keep the base rate at 5.25% for a second month on the back of a further decline in inflation in August. It was the first break in the UK’s rising rate cycle […]
-
12 Jun 2023 1 min read
Bargain Hunter: sizing up ‘cheap’ investment trusts on 5%-plus yields
by Kyle Caldwell from interactive investor, 8 June 2023: For investment trust fans now is one of the best opportunities over the past decade to try and pick up a bargain, as the chart below from stockbroker Numis shows. The average equity investment trust is trading on a discount a smidge over 10%, while those […]
-
01 Jun 2023 1 min read
Investment trusts ditch their ‘inflation protection’ tag
By Val Cipriani, Investors’ Chronicle, June 1, 2023: Investment trusts are announcing below-inflation dividend increases, making it more difficult for investors to maintain the real value of their income – although some might be able to catch up in 2024 or 2025. Last week, core infrastructure trust HICL Infrastructure (HICL) said it intends to maintain […]
-
18 Apr 2023 1 min read
Investment trust insider on discounts
James Carthew: This selloff has gone too far Looking at my portfolio, the past few months have felt a bit frustrating. Investment companies that I am convinced are sound have been derated, sometimes aggressively. Investors seem irrational, perhaps even panicky. Fundamentals are being ignored and sentiment rules all. Fortunately, the bulk of my investments are […]
-
20 Apr 2022 1 min read
Defensives doing well
Jennifer Hill, AIC Compass, 8 April 2022: Jennifer Hill analyses the sectors delivering robust returns. Russia’s invasion of Ukraine feels symbolic, not only of a marked change in the geopolitical landscape but also of a potential regime change in investing. With oil, gas, wheat and many metals soaring in price, already-stubborn inflation is likely to […]
-
21 Jan 2022 1 min read
The investment trust themes to watch out for in 2022
30th December 2021 by Faith Glasgow from interactive investor At the end of 2020, we looked ahead into the coming year and tried to pick out some key trends likely to shape the investment trust industry in 2021. It was a difficult, locked-down time, but our experts accurately identified several important themes. Most significant was […]
-
23 Dec 2021 2 min read
Gaining exposure to biotech in times of uncertainty
Robin Davison, Investment Week, 13 December 2021 The end of November saw the largest one-day fall in stock prices globally since June 2020, as investors reacted to the potential economic impact of a possible fourth wave of Covid-19, manifest in the new and ominously named Omicron variant of the Sars-Cov-2 virus. But the panic selling […]
-
04 Jan 2021 1 min read
2020’s investment trust winners: time to take profits?
2020’s investment trust winners: time to take profits? December 30, 2020 By Dave Baxter The enormous sell-off that took hold in February and March was swiftly followed by a fierce rally that has come to dominate much of the year. MSCI World index rose by nearly 40 per cent in sterling terms between the start of […]
-
01 Oct 2019 2 min read
QuotedData’s input into Investors Chronicle’s Top 100 Funds
Top 100 Funds 2019: Specialist equity funds By Leonora Walters If you have a large portfolio and a higher risk appetite, you could consider adding a small allocation to some specialist equities funds focused on a particular area that could benefit from high growth… NEW ENTRANT:Polar Capital Global Insurance(IE00B61MW553): Insurance company equities can be a good […]
-
09 Aug 2018 1 min read
Biotech and commodity trusts top performance tables in July
After months of volatility, investment trusts in the biotech and commodity sectors were the winners in July in both price and NAV terms, according to latest figures. In its monthly investment companies round-up, trust analysts QuotedData revealed biotech and commodity investment trusts – which have had a difficult time over the last few months in […]
-
17 Mar 2017 1 min read
Biotech trusts top performance charts in February
Biotech and healthcare trusts came at the top of performance tables in NAV terms in February, as the sector continues to “claw back losses” suffered prior to the US election, according to investment trust analysts QuotedData. read more here
-
29 Nov 2016 1 min read
Biotech trust Trump benefit may be shortlived
Markets experienced considerable gyrations in the aftermath of the election of Donald Trump as US president, and investment trusts didn’t escape the action, with trusts rising as well as falling sharply. However, these moves are not necessarily an indication of what lies ahead and some of the fallers may offer some value. read more here
